Changing treatment goals for acute lymphoblastic leukemia (ALL): Are you and your healthcare team on the same page?

Dawn Maze is an Assistant Professor in the Department of Medicine at the University of Toronto and a Clinician Investigator in the Leukemia and Myeloproliferative Neoplasms (MPN) Programs at the Princess Margaret Cancer Centre. Her interests include risk stratification and management of acute leukemia and MPN, particularly in the adolescent and young adult (AYA) population. She is the primary investigator or co-investigator on several enrolling and upcoming clinical trials of novel therapies for myeloid neoplasms. She is currently serving as the Medical Director for the Malignant Hematology Day Unit at Princess Margaret and as the Director for the Leukemia Fellowship Program.